Abstracts

Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI

Background: HIV infection is a major global health problem with ART-free viral control remaining an unmet need. PD-1 blockade offers a promising approach to help address this. We conducted a phase 1b randomized double-blind study (NCT04223804) with an investigational PD-1 inhibitor, budigalimab, in people living with HIV-1 (PLWH) and included planned analytical treatment interruption (ATI)…

Sex-Specific Innate Immune Selection in Vertical HIV Transmission and cART-Free Aviraemia in Males

Background: Following case reports of paediatric post-treatment control, it has been proposed that very early cART without additional interventions might achieve remission in a subset of children. To investigate this possibility, from 2015-2023 we conducted a longitudinal study of >300 mother-child pairs in KwaZulu-Natal, South Africa monitored from birth after in utero HIV transmission. Methods:…

Early Bactericidal Activity of the Alpibectir-Ethionamide (AlpE) Combination Against Tuberculosis

Background: Dose-dependent tolerability reduces the utility of ethionamide for tuberculosis (TB) treatment at standard doses (750 to 1000 mg). Alpibectir (formerly BVL-GSK098) stimulates an alternative pathway of bacterial ethionamide bioactivation leading to retained activity at lower exposures in vivo. We report results on the first cohort evaluating the early bactericidal activity (EBA), safety and tolerability…

Virologic Outcomes With Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure

Background: Patients failing protease inhibitor (PI)-based 2nd-line antiretroviral therapy (ART) in the South African ART programme qualify for genotypic antiretroviral resistance testing (GART) – those with PI resistance receive a darunavir (DRV/r)-based 3rd-line regimen; those without PI resistance continue their regimen with adherence support. In the Western Cape Province from September 2020, an adaption to…

Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis on Rifampicin at Week 24

Background: Integrase strand transfer inhibitors, bictegravir (BIC) and dolutegravir (DTG), are currently recommended for the treatment of HIV. However, the efficacy, safety, and pharmacokinetics (PK) of BIC in people with HIV (PWH) and tuberculosis (TB) taking rifampicin-based therapy has not been evaluated. Methods: INSIGHT (NCT04734652) is an open-label, non-comparative, phase-2b randomised controlled trial in ART-naïve…